B-intervention	0	3	DNA
I-intervention	4	10	repair
I-intervention	11	15	gene
I-intervention	16	26	expression
O	27	30	and
O	31	35	risk
O	36	38	of
O	39	51	locoregional
O	52	59	relapse
O	60	62	in
O	63	69	breast
O	70	76	cancer
O	77	85	patients
O	85	86	.

O	87	96	Radiation
O	97	104	therapy
O	105	112	appears
O	113	115	to
O	116	120	kill
O	121	126	cells
O	127	133	mainly
O	134	136	by
O	137	145	inducing
O	146	149	DNA
O	150	156	double
O	156	157	-
O	157	163	strand
O	164	170	breaks
O	170	171	.

O	172	174	We
O	175	187	investigated
O	188	195	whether
O	196	199	the
O	200	203	DNA
O	204	210	repair
O	211	215	gene
O	216	226	expression
O	227	233	status
O	234	239	might
O	240	249	influence
O	250	253	the
O	254	258	risk
O	259	261	of
O	262	274	locoregional
O	275	285	recurrence
O	286	287	(
O	287	290	LRR
O	290	291	)
O	292	294	in
O	295	301	breast
O	302	308	cancer
O	309	317	patients
O	317	318	.

O	319	321	We
O	322	326	used
O	327	328	a
O	329	341	quantitative
O	342	349	reverse
O	350	363	transcriptase
O	364	367	PCR
O	367	368	-
O	368	373	based
O	374	382	approach
O	383	385	to
O	386	393	measure
O	394	403	messenger
O	404	407	RNA
O	408	414	levels
O	415	417	of
O	418	420	20
O	421	429	selected
O	430	433	DNA
O	434	440	repair
O	441	446	genes
O	447	449	in
O	450	455	tumor
O	456	463	samples
O	464	468	from
B-total-participants	469	471	97
O	472	478	breast
O	479	485	cancer
O	486	494	patients
O	495	503	enrolled
O	504	506	in
O	507	508	a
O	509	514	phase
O	515	518	III
O	519	524	trial
O	525	526	(
O	526	532	Centre
O	533	536	Ren
O	536	537	Ã©
O	538	546	Huguenin
O	547	553	cohort
O	553	554	)
O	554	555	.

O	556	566	Normalized
O	567	571	mRNA
O	572	578	levels
O	579	583	were
O	584	590	tested
O	591	594	for
O	595	597	an
O	598	609	association
O	610	614	with
O	615	618	LRR
O	618	619	-
O	619	623	free
O	624	632	survival
O	633	634	(
O	634	637	LRR
O	637	638	-
O	638	640	FS
O	640	641	)
O	642	645	and
O	646	653	overall
O	654	662	survival
O	663	664	(
O	664	666	OS
O	666	667	)
O	667	668	.

O	669	672	The
O	673	681	findings
O	682	686	were
O	687	696	validated
O	697	699	in
O	700	710	comparison
O	711	715	with
O	716	721	those
O	722	724	of
O	725	727	an
O	728	739	independent
O	740	746	cohort
O	747	748	(
O	748	759	Netherlands
O	760	766	Cancer
O	767	776	Institute
O	777	778	(
O	778	781	NKI
O	781	782	)
O	783	789	cohort
O	789	790	)
O	790	791	.

O	792	804	Multivariate
O	805	813	analysis
O	814	826	encompassing
O	827	832	known
O	833	843	prognostic
O	844	851	factors
O	852	855	was
O	856	860	used
O	861	863	to
O	864	870	assess
O	871	874	the
O	875	886	association
O	887	894	between
O	895	898	DNA
O	899	905	repair
O	906	910	gene
O	911	921	expression
O	922	925	and
O	926	933	patient
O	934	941	outcome
O	941	942	.

O	943	948	RAD51
O	949	952	was
O	953	956	the
O	957	961	only
O	962	966	gene
O	967	977	associated
O	978	982	with
O	983	986	LRR
O	987	989	in
O	990	994	both
O	995	1002	cohorts
O	1002	1003	.

O	1004	1008	With
O	1009	1010	a
O	1011	1017	median
O	1018	1024	follow
O	1024	1025	-
O	1025	1027	up
O	1028	1030	of
O	1031	1034	126
O	1035	1041	months
O	1042	1044	in
O	1045	1048	the
O	1049	1052	CRH
O	1053	1059	cohort
O	1059	1060	,
O	1061	1064	the
O	1065	1066	5
O	1066	1067	-
O	1067	1071	year
O	1072	1075	LRR
O	1075	1076	-
O	1076	1078	FS
O	1079	1082	and
B-outcome	1083	1085	OS
O	1086	1091	rates
O	1092	1096	were
B-iv-bin-percent	1097	1100	100
I-iv-bin-percent	1100	1101	%
O	1102	1105	and
B-iv-bin-percent	1106	1108	95
I-iv-bin-percent	1108	1109	%
O	1110	1112	in
O	1113	1116	the
B-intervention-participants	1117	1119	61
O	1120	1128	patients
O	1129	1133	with
B-intervention	1134	1137	low
I-intervention	1138	1143	RAD51
I-intervention	1144	1154	expression
O	1154	1155	,
O	1156	1164	compared
O	1165	1169	with
B-cv-bin-percent	1170	1172	70
I-cv-bin-percent	1172	1173	%
O	1174	1177	and
B-cv-bin-percent	1178	1180	69
I-cv-bin-percent	1180	1181	%
O	1182	1184	in
O	1185	1188	the
B-control-participants	1189	1191	36
O	1192	1200	patients
O	1201	1205	with
B-control	1206	1210	high
I-control	1211	1216	RAD51
I-control	1217	1227	expression
O	1227	1228	,
O	1229	1241	respectively
O	1242	1243	(
O	1243	1244	p
O	1245	1246	<
O	1247	1248	0
O	1248	1249	.
O	1249	1252	001
O	1252	1253	)
O	1253	1254	.

O	1255	1260	RAD51
O	1261	1275	overexpression
O	1276	1279	was
O	1280	1290	associated
O	1291	1295	with
O	1296	1297	a
O	1298	1304	higher
B-outcome	1305	1309	risk
I-outcome	1310	1312	of
I-outcome	1313	1316	LRR
O	1317	1318	(
O	1318	1324	hazard
O	1325	1330	ratio
O	1331	1332	[
O	1332	1334	HR
O	1334	1335	]
O	1335	1336	,
O	1337	1339	12
O	1339	1340	.
O	1340	1342	83
O	1342	1343	;
O	1344	1346	95
O	1346	1347	%
O	1348	1358	confidence
O	1359	1367	interval
O	1368	1369	[
O	1369	1371	CI
O	1371	1372	]
O	1372	1373	,
O	1374	1375	3
O	1375	1376	.
O	1376	1377	6
O	1377	1378	-
O	1378	1380	45
O	1380	1381	.
O	1381	1382	6
O	1382	1383	)
O	1384	1387	and
B-outcome	1388	1393	death
O	1394	1395	(
O	1395	1397	HR
O	1397	1398	,
O	1399	1400	4
O	1400	1401	.
O	1401	1403	10
O	1403	1404	;
O	1405	1407	95
O	1407	1408	%
O	1409	1411	CI
O	1411	1412	,
O	1413	1414	1
O	1414	1415	.
O	1415	1416	7
O	1416	1417	-
O	1417	1418	9
O	1418	1419	.
O	1419	1420	7
O	1420	1421	)
O	1421	1422	.

O	1423	1428	RAD51
O	1429	1443	overexpression
O	1444	1447	was
O	1448	1452	also
O	1453	1466	significantly
O	1467	1477	associated
O	1478	1482	with
O	1483	1490	shorter
B-outcome	1491	1494	LRR
I-outcome	1494	1495	-
I-outcome	1495	1497	FS
I-outcome	1498	1501	and
I-outcome	1502	1504	OS
O	1505	1507	in
O	1508	1511	the
O	1512	1515	NKI
O	1516	1522	cohort
O	1522	1523	.

O	1524	1538	Overexpression
O	1539	1541	of
O	1542	1547	RAD51
O	1547	1548	,
O	1549	1550	a
O	1551	1554	key
O	1555	1564	component
O	1565	1567	of
O	1568	1571	the
O	1572	1582	homologous
O	1583	1586	DNA
O	1587	1593	repair
O	1594	1601	pathway
O	1601	1602	,
O	1603	1605	is
O	1606	1616	associated
O	1617	1621	with
O	1622	1626	poor
O	1627	1633	breast
O	1634	1640	cancer
O	1641	1648	outcome
O	1648	1649	.

O	1650	1654	This
O	1655	1662	finding
O	1663	1671	warrants
O	1672	1683	prospective
O	1684	1691	studies
O	1692	1694	of
O	1695	1700	RAD51
O	1701	1703	as
O	1704	1705	a
O	1706	1720	prognosticator
O	1721	1724	and
O	1725	1736	therapeutic
O	1737	1743	target
O	1743	1744	.
